期刊文献+

米非司酮壳型阴道环的制备方法及体外释放度研究 被引量:2

Preparation and in-Vitro Evaluation of the Shell Vaginal Ring Containing Mifepristone
原文传递
导出
摘要 目的研制米非司酮壳型阴道环,并考察其体外释放度。方法首先将药物制备成以PVPK-30为载体的固体分散体,采用差式扫描量热法和X-射线衍射法进行表征。然后以硅橡胶为载体,采用热压硫化法制备米非司酮壳型阴道环,环内层为空白硅橡胶骨架,中间为含药部分,最外层为无活性的硅橡胶薄膜。以200 mL(pH 4.0)磷酸盐缓冲液为释放介质,采用紫外-可见分光光度法考察米非司酮阴壳型道环的体外释放度。结果米非司酮壳型阴道环释药更为平稳,每日平均释放药物1 mg,持续释放时间至少达21 d,且批间差异小。结论采用米非司酮固体分散体制备的壳型阴道环具有良好的缓控释特性,制备工艺稳定。采用紫外-可见分光光度法考察阴道环的体外释放度更方便、快速和准确。 OBJECTIVE To prepare and in vitro evaluate the shell vaginal ring(VR) containing mifepristone. METHODS The solid dispersion of mifepristone with PVP k30 as a carrier was prepared and characterized by the methods of differential scanning calorim- etry (DSC) and X-ray diffraction analysis (XRD). The shell vaginal ring containing mifepristone was prepared by the method of mold molding process, the inner layer of vaginal ring is the blank silastie skeleton, the middle layer of vaginal ring is the part containing drug, the outermost layer is a non-active silicon rubber membrane. In vitro drug release test was conducted in a dissolution apparatus, release medium was 200 mL PBS ( pH 4. 0) meeting with sink conditions, and release samples were determined by the UV-vis spectro- photometry. RESULTS The shell vaginal ring containing mifepristone had a steady drug release rate in vitro during 21 d. The daily release of rnifeprisotne was about 1 mg, which sustained two weeks at least at this release rate, and the variance intra- batch was very small. CONCLUSION The shell vaginal ring containing mifepristone exhibits the sustained and controlled release characteristics in vitro,and the preparation method is stable. The developed UV-vis method is rapid, accurate and convenient.
出处 《中国药学杂志》 CAS CSCD 北大核心 2013年第9期720-724,共5页 Chinese Pharmaceutical Journal
基金 十二五国家科技支撑计划课题(2012BAI31B00)
关键词 米非司酮 固体分散体 壳型阴道环 缓控释 紫外-可见分光光度法 mifepristone solid dispersion shell vaginal ring sustained release UV-vis spectrophotometry
  • 相关文献

参考文献4

二级参考文献55

共引文献19

同被引文献36

  • 1高艳丽,肖琰,梁金英,朱萱萱,李瑛,刘建平.孕二烯酮-炔雌醇双层贴剂的制备及体内外评价(英文)[J].中国药科大学学报,2009,40(5):416-420. 被引量:2
  • 2周菊贤,刘晓瑷.新型非口服激素避孕方式的研究进展[J].国际生殖健康与计划生育杂志,2009,28(4):245-248.
  • 3LAKHA F,HO PC, VAN DER SPUY ZM,et al. A novel estro- gen-free oral contraceptive pill for women: muhicentre, double- blind, randomized controlled trial of mifepristone and progestogen- only pill ( levonorgestrel ) [ J ]. Hum Reprod, 2007, 22 ( 9 ) : 2428 - 2436.
  • 4PEI KY, XIAO BL, JING XP, et al. Weekly contraception with mifepristone [ J ]. Contraception,2007,75 ( 1 ) :40 - 44.
  • 5AGARWAL M, DAS V,AGARWAL A,et al. Evaluation of mife- pristone as a once a month contraceptive pill[ J J. Am J Obstet Gyneeol, 2009,200 (5) :27 - 29.
  • 6CHANG YF,SEAN M ,KEVIN F. Improved quality of life is part- [y explained by fewer symptoms after treatment of fibroids with mifepristone [ J ]. lnt J Gynecolobstet,2010,109 ( 2 ) : 121 - 124.
  • 7D'HOOGHE TM. Clinical relevance of the baboon as a model for the study of endometrinsis [ J ]. Fertil Steril, 1997,68 ( 4 ) : 613 - 625.
  • 8BAGARIA H, SUNEJA A, VAID NB,et al. Low-dose mifepris- tone in treatment of uterine leiomyoma : a randomised double-blind placebo-controlled clinical trial[ J]. Aust N Z J Obstet Gynaecol, 2009,49(1) :77 -83.
  • 9ENGMAN M,GRANBERG S,WILLIAMS AR,et al. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial[ J ]. Hum Reprod, 2009,24 ( 8 ) : 1870 - 1879.
  • 10QUEREUX C,RAIMOND E, GRAESSLIN O. Oral contraceptives and non-oral contraceptives: realities [ J]. J Fynecol Obstet Biol Reprod(Paris) ,2009,5 ( 38 ) :69 - 83.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部